| 2.28 0.08 (3.64%) | 08-21 10:58 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.79 | 1-year : | 3.26 |
| Resists | First : | 2.39 | Second : | 2.79 |
| Pivot price | 1.82  |
|||
| Supports | First : | 1.78 | Second : | 1.4 |
| MAs | MA(5) : | 2.12 |
MA(20) : | 1.75 |
| MA(100) : | 1.72 |
MA(250) : | 1.82 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 88.9 |
D(3) : | 90 |
| RSI | RSI(14): 67 |
|||
| 52-week | High : | 3.55 | Low : | 1.26 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ACRV ] has closed below upper band by 11.9%. Bollinger Bands are 92.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.39 - 2.4 | 2.4 - 2.41 |
| Low: | 2.04 - 2.05 | 2.05 - 2.06 |
| Close: | 2.37 - 2.39 | 2.39 - 2.41 |
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
Thu, 20 Aug 2026
Acrivon Therapeutics (ACRV) CLO sells 185 shares for taxes - Stock Titan
Thu, 20 Aug 2026
Acrivon Therapeutics (ACRV) insider offloads 400 shares for taxes - Stock Titan
Thu, 20 Aug 2026
Acrivon Therapeutics (ACRV) COO’s tax sale leaves 146,349 shares - Stock Titan
Thu, 20 Aug 2026
Acrivon (NASDAQ: ACRV) chiefs sell shares to cover RSU taxes - Stock Titan
Thu, 13 Aug 2026
Sands Capital group (NASDAQ: ACRV) discloses 5.3% Acrivon ownership in 13G/A - Stock Titan
Thu, 06 Aug 2026
Acrivon Therapeutics, Inc. (ACRV) CFO sells 1,142 shares to cover taxes - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 43 (M) |
| Shares Float | 28 (M) |
| Held by Insiders | 15.4 (%) |
| Held by Institutions | 47.4 (%) |
| Shares Short | 1,490 (K) |
| Shares Short P.Month | 2,830 (K) |
| EPS | -2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.46 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -36.3 % |
| Return on Equity (ttm) | -60.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.9 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -65 (M) |
| Levered Free Cash Flow | -41 (M) |
| PE Ratio | -1.11 |
| PEG Ratio | 0 |
| Price to Book value | 0.89 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.46 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|